Collaboration
Celebrating the success of the Region of Learning project
Reflecting on a phenomenal journey: Celebrating the success of the Region of Learning project in the greater Cambridgeshire and Peterborough regions. ...
Apprenticeship Careers Fair 2024 Inspires Over 1200 Students
Our annual Apprenticeship Careers Fair 2024 kicked off on 30 January 2024 with much enthusiasm as over 1200 students flocked to Impington Village College to explore a wide variety of apprenticeship opportunities presented by 26 esteemed Cambridgeshire employers. ...
Inspiring over 450 students at Form the Future’s 3rd annual Primary Careers Fair
Form the Future welcomed over 450 children to meet with 24 businesses at Cambridge Regional College for the Greater Cambridge Partnership (GCP) Primary School Careers Fair on Tuesday, 5 March 2024. Children aged 9 to 11 years old from 9 Cambridgeshire-based schools explored a wide range...
Celebrating DNA Day with HRH The Princess Royal and Illumina
“Imagine getting to work in a place like this every day. I’m going to be a scientist!” ...
Make a Difference: Become a Mentor with Form the Future
Have you ever wanted to make a positive impact on a young person’s life? Mentoring could be the perfect opportunity. Recently, I had the chance to speak with Sonny Kurmi, a Chartered Financial Adviser at S K Wealth Solutions, who has been mentoring with Form the Future for just over a y...
Experience AI expands to reach over 2 million students
Philip Colligan writes: two years ago, we announced Experience AI, a collaboration between the Raspberry Pi Foundation and Google DeepMind to inspire the next generation of AI leaders. ...
GSK establishes new subsidiary in Shanghai's Lingang new area
GlaxoSmithKline (GSK), the renowned British biopharmaceutical company, has taken a significant step in expanding its presence in China. On September 10, the unveiling ceremony of Shanghai GlaxoSmithKline Pharmaceuticals Co., Ltd. was held in Lingang Centre, marking its official establ...
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies Cancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing Phase 1/2a clinical trial o...
New therapy that targets and destroys tau tangles is a promising future Alzheimer’s disease treatment
Medical Research Council media release.